We are thrilled to announce our latest article in #Pharmaceutics: "Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies." Dive into groundbreaking research by Sabina Paglialunga, Natacha Benrimoh, and Aernout van Haarst from Celerion that tackles the complexities of transporter DDIs using innovative methodologies. Read now: https://lnkd.in/eZgEMSFT #DDI #DrugDevelopment #Pharmacokinetics #ClinicalResearch
Celerion’s Post
More Relevant Posts
-
We are thrilled to announce our latest article in #Pharmaceutics: "Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies." Dive into groundbreaking research by Sabina Paglialunga, Natacha Benrimoh, and Aernout van Haarst from Celerion that tackles the complexities of transporter DDIs using innovative methodologies. Read now: https://lnkd.in/eZgEMSFT #DDI #DrugDevelopment #Pharmacokinetics #ClinicalResearch
-
-
📢 Check out our latest review article on Transporter DDI studies!
We are thrilled to announce our latest article in #Pharmaceutics: "Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies." Dive into groundbreaking research by Sabina Paglialunga, Natacha Benrimoh, and Aernout van Haarst from Celerion that tackles the complexities of transporter DDIs using innovative methodologies. Read now: https://lnkd.in/eZgEMSFT #DDI #DrugDevelopment #Pharmacokinetics #ClinicalResearch
-
-
Senior Vice President of Research and Development at Certara UK, Predictive Technologies Division, FAAPS
Would you like to know how PBPK modelling can be used to save more than 10 clinical pharmacology studies? Please make sure you are attending this talk by Ioannis Loisios-Konstantinidis.
Join us at #CERTAINTY Europe on Oct 29! Dr. Ioannis Loisios-Konstantinidis of Novartis will reveal how PBPK modeling replaced 10+ clinical studies in Scemblix’s NDA, shaping regulatory review and drug labeling. See the full agenda and register: https://lnkd.in/eq9XeUXY #CertaintybyCertara #DrugDevelopment #MIDD
-
-
Providing best in class cheminformatics solutions and services for the pharma and biotech industry
Chemaxon and Certara finally as one company, bringing you the next generation of a more precise, model-informed Drug Discovery and Development, with improved certainty in decision-making throughout. Join us for a live webinar on 20th Nov with Certara's CEO William Feehery and Chemaxon's CEO Richard Jones to learn more and be sure to check out our press release below
Chemaxon and Certara are now bonded! Together we are transforming drug discovery and development bringing the next generation of medicines to patients faster and with greater certainty. “Together, we will offer clients the ability to broadly conduct in-silico research to inform better decision-making at every phase of development.” Richard Jones, Chemaxon’s CEO. Learn more about the news directly from Certarta CEO William Feehery and Chemaxon CEO Richard Jones when they will share what is next at this Nasdaq sponsored webinar Nov 20: https://lnkd.in/gW-jTP7W Read the press release for more details: https://lnkd.in/gkWF_Bfm
-
📌 Missed the new ENETS-NANETS-Webinar: Highlights of PRRT and drug development abstracts? Now you can watch the video recording from the most prominent NEN experts from Europe and USA on clinical trials updates related to GEP NETs and #pheochromocytomas/#paragangliomas. ☑ Watch here: https://lnkd.in/dbDUuedg #LetsTalkAboutNETs #NeuroendocrineCancer
-
-
Pharmacist | MS Pharm. Tech. | Scientific Reviewer | Academic Writer | Thesis on Phyto-Pharmacology of Natural Product | Product Executive, PMD
Happy to share my latest article, "From Prodrug to Multimatrix: Recent Advancements in Colon-Specific Drug Delivery Systems," now published in Sciences of Pharmacy. Available on: https://lnkd.in/g5DniyYU #Colon_Specific_Drug #CSDDS #Drug_Delivery #Prodrug #Multimatrix #3D_bicompartmental_device #MMX_Technology #Phloral_technology
-
-
Across my time at the FDA and Industry, I have learned the importance of being an effective story teller and how this helps position a development program to receive useful insights from regulatory agencies. My collegues Matthew Hight, PhD, RAC , Joshua Taylor, PhD, RAC, and I have shared insights from our experiences engaging the FDA in formal meetings and approaches to leverage these insights while preparing for and attending Pre-NDA and Pre-BLA meetings. Please enjoy these insights as you read and share the blog post below here! #Allucent #BringNewTherapiesToLight #ClinicalTrials #DrugDiscovery #FDAApproval #RegulatorySubmissions
In this next part of our series on formal FDA meetings, Allucent experts Matthew Hight, PhD, RAC, Joshua Taylor, PhD, RAC, and Marcus Delatte, PhD divulge how to help sponsors prepare for discussions with the FDA for their upcoming new drug application (NDA) or biologic license application (BLA), following the completion of related pivotal clinical studies. This blog delves into topics such as: - Objectives of the Pre-NDA/BLA meeting - Crafting effective FDA Meeting Requests and Packages - Important topics to discuss during pre-NDA/BLA meeting Read the blog to learn more: https://lnkd.in/gTnykQef #Allucent #BringNewTherapiesToLight #ClinicalTrials #DrugDiscovery #FDAApproval #RegulatorySubmissions
-
-
Join us in celebrating Sirona Dx and their wins! -Sirona leads in profiling complex biology at single-cell resolution for precision biomarker signatures. Their team's expertise has attracted 9 of the top 20 global pharma companies, and new contracts in 2024 are expected to triple revenue compared to 2023. -In addition to maintaining their CLIA accreditation and passing the last 3 audits with Zero Deficiency, our QA team developed and implemented an advanced Quality Management System enabling us to operate under GCLP guidelines and support two Phase 2 clinical trial studies in 2024. An important aspect of this includes the development of leading edge, validation strategies, enabling clients to submit single cell biology readouts in FDA submissions. -Secured contracts for our specialized single cell multi omics and spatial biology capabilities with numerous leading pharma and biotech companies including a $1.4M contract to support a phase 2 clinical trial. #OBI4You #BioTechWins
-
-
Gain insights directly from users: Zhejiang Longcharm Biomedicine Technology, a leading Chinese CRO, decided to adopt Pinnacle 21 Enterprize for sponsors to deliver high-quality CDISC data. What impact did this adoption have? Discover the advantages for both sponsors and the CRO. Dive into the details with the Voice of Customer article from Longcharm Bio: https://ow.ly/8hg350QBhXE #P21E #CDISC #CRO
-
🧬 The first and last name in scientific Discovery 💊 I am excited to see the positive impact we will have for our customers: ➡️ Removing friction from research processes ➡️ Bringing ever larger datasets within easier reach ➡️ Using mechanistic modelling to explore the previously unexplorable ➡️ Positively exploiting AI to iterate quickly towards suggesting only those solutions that we know will be safe and highly efficacious across many diverse populations
Chemaxon and Certara are now bonded! Together we are transforming drug discovery and development bringing the next generation of medicines to patients faster and with greater certainty. “Together, we will offer clients the ability to broadly conduct in-silico research to inform better decision-making at every phase of development.” Richard Jones, Chemaxon’s CEO. Learn more about the news directly from Certarta CEO William Feehery and Chemaxon CEO Richard Jones when they will share what is next at this Nasdaq sponsored webinar Nov 20: https://lnkd.in/gW-jTP7W Read the press release for more details: https://lnkd.in/gkWF_Bfm
Felix Perez, CEO Research Director
2moCongratulations! The innovative approaches outlined in the article sound fascinating and crucial for advancing our understanding of transporter DDIs. #DDI #DrugDevelopment